SEC Form 4 · accession 0001209191-18-046163
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Arkowitz
Officer — Chief Financial Officer
Period of report
Aug 9, 2018
Accepted (ET)
Aug 10, 2018 · 12:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 9, 2018 | P | 4,000 | $23.42 | A | 44,250 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The weighted average purchase price for the transaction reported was $23.42, and the range of prices were between $23.3525 and $23.4288. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.